IO NewsWire

January 24, 2011 07:30 ET

(NASDAQ: KERX) Under The Radar

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire.

NEW YORK, NY--(Marketwire - January 24, 2011) - Keryx Biopharmaceuticals (NASDAQ: KERX) has recently announced its participation at the 29th Annual J.P. Morgan Healthcare Conference; audio of the presentation is available at

Keryx maintains "Buy" and "Market Outperform" ratings from Ladenburg Thalmann and Rodman & Renshaw respectively.

Keryx currently has two drugs in Phase III with the FDA, the anticipated successful results should help the company outperform current estimates.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease.

For more information, please visit

Other active stocks are AEterna Zentaris (NASDAQ: AEZS) Pfizer (NYSE: PFE) and Novartis (NYSE: NVS)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information